Navigation Links
Qualyst Transporter Solutions, LLC Announces New Alliance with GenoMembrane

RESEARCH TRIANGLE PARK, N.C., Jan. 21, 2013 /PRNewswire-iReach/ -- Qualyst Transporter Solutions, LLC, has recently announced an alliance with GenoMembrane, Kanagawa, Japan to make available its B-CLEAR® Technology to customers in Japan.  The initial offering will focus on supplying B-CLEAR® kits of rat and human hepatocytes, both plated with Transporter Certified™ hepatocytes.  In addition, contract services projects can be facilitated through GenoMembrane.  The alliance will facilitate access to B-CLEAR® technology in Japan, which can be used to predict the biliary excretion of drugs, evaluate clinically relevant drug interactions, determine the cholestatic potential of drugs, and estimate their intracellular concentration.

"B-CLEAR® human kits for Japan use cryopreserved human hepatocytes that have been certified for transporter function (uptake and efflux), providing the customer with clinically relevant data, and a high level of reproducibility from experiment to experiment." said Dr. Christopher Black , CEO for Qualyst Transporter Solutions.

Qualyst Transporter Solutions only uses Transporter Certified™ hepatocytes in its kits and services to examine the potential for in vivo relevant transporter-based drug interactions.  The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning cell system that has been certified for transporter function.  "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees that the results are in vivo-relevant," said Dr. Kenneth Brouwer , CSO for Qualyst Transporter Solutions.

"We are excited that we can now offer B-CLEAR® kits with both rat and human hepatocytes to our Japanese customers, as well as an opportunity to offer other relevant research services conducted by Qualyst Transporter Solutions," said Mr. Satoshi Senda , CEO for GenoMembrane.

About Qualyst Transporter Solutions, LLC
In addition to it's patented B-CLEAR® technology, Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development.  Qualyst Transporter Solutions products provide answers to transporter questions that arise in drug discovery and development.  For additional information, please refer to the company's web site at or call (919) 313-6500.  B-CLEAR® technology is covered by US (# 6780580), EU (#1163517) and JP (#4451570) patents issued and pending.

About GenoMembrane
GenoMembrane Co., Ltd. provides transporter-related products and services that are critical in the development and design of novel drugs for clinical applications.  GenoMembrane also provides research tools and collaborates for the pharmacological evaluation of drug candidates to minimize costs, help improve the success rate of candidate drugs, and speed up new drug development. For additional information, please refer to the company's web site at

Media Contact

US:  Qualyst Transporter Solutions, Christopher Black , Ph.D. Chief Executive Officer, (919) 313-6511,

Japan: GenoMembrane, Satoshi Senda , Chief Executive Officer, +81(45)508-2326,

Media Contact: Christopher Black Qualyst Transporter Solutions, LLC, 9192978681,

News distributed by PR Newswire iReach:

SOURCE Qualyst Transporter Solutions, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
3. Catalent Pharma Solutions, Inc. Announces Increase In Tender Cap For Its Cash Tender Offer For Its 9-1/2%/10-1/4% Senior PIK-Election Notes Due 2015
4. Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015
5. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
6. Frost & Sullivan Recognizes Terso Solutions, Inc. with 2012 Best Practices Award
7. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
8. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
9. Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology
10. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
11. Express Scripts Holding Company Announces Fourth Quarter 2012 Earnings Conference Call
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Asia ... which BioLight and the New Investors will make a ... via a private placement. The financing will help IOPtima ... system used in the treatment of glaucoma, as well ... the IOPtimate™ system with the U.S. Food and Drug ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Developmental, commercial, and regulatory/legal strategies ... of pharmaceutical products, says GBI Research ... strategies all play a key role in boosting the ... . --> Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... seniors, is resulting in a way for homeless people to have a more ... launched a new initiative whereby they are repurposing plastic bags into sleeping mats ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Many people ... fatigue, fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find ... diet and exercise regimen instead of their thyroid, especially if they don’t have any ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit ... as well as raising public awareness of the disorder while helping to bring ... donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center at ...
(Date:11/25/2015)... ... 25, 2015 , ... Since its launch in 2012, the ... stem cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. ... Trademark (RTM). , Organizations are required to hold a registered trademark in order ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):